利用組織微陣列評估GIT-1與犬隻乳房腫瘤之相關性:2005-2009

GIT-1 and Canine Mammary Gland Tumor - A Tissue Microarray Study (2005-2009)

康文(Wen Kang)

指導教授 ： 李繼忠

共同指導教授 ： 林中天

國立臺灣大學/獸醫專業學院/臨床動物醫學研究所/碩士(2011年)

https://doi.org/10.6342/NTU.2011.02293

摘要

無資料

關鍵字

GIT1 ； 犬隻乳房腫瘤 ； 組織微陣列

並列摘要

Mammary gland tumors are among the most common tumors of the female dog. Recent studies have shown multiple risk factors and over-expressions of proteins that are highly associated with patient prognosis and overall survival. GIT-1 is a protein that appears to be associated with the regulation of cytoskeleton dynamics during cell spreading and migration. Recent evidence suggests that GIT-1 could be involved in human Huntington’s disease due to altered membrane trafficking. The role of GIT-1 over-expression in canine mammary gland tumor is currently unknown. However, through the microarray techniques adopted in this study, immunohistochemistry (IHC) significance of 90% was noted. Our goal is to identify the significance of GIT-1 IHC staining in canine mammary gland tumor and further connect these results with their clinical prognosis. 61 cases were collected through the years of 2005 to 2009. 58 dogs (95%) came up with a positive GIT-1 staining result. The dogs were grouped according to their IHC scores. The group with the higher IHC scores (≥3) reached an median survival of 361 days, whereas the lower IHC scoring group (≤2) had a median survival of 574 days, no significance was noted (p=0.94). The patient’s GIT1 significance were also compared with its WHO modified TNM staging scores, however still no significance was achieved (p=0.117). Nevertheless, we did manage to prove that the TNM staging system provided a rough understanding of the patient’s survival (p=0.015). We conclude that there was no significance noted between IHC scorings and patient prognosis.

並列關鍵字

GIT1 ； canine mammary gland tumor ； tissue microarray

參考文獻

2. Amorim I, Lopes CC, Faustino AMR et al: Immunohistochemical expression of calveolin-1 in normal and neoplastic canine mammary tissue, J Comp Path 143:39-44, 2010.

4. Chang CC, Tsai MH, Liao JW et al: Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors, J Am Vet Med Assoc 235:391–396, 2009.

5. Dore M, Lanthier I, Sirois J: Cyclooxygenase-2 expression in canine mammary tumors, Vet Pathol 40:207-212, 2003.

6. Dorn CR, Taylor DON, Schneider R et al: Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County, J Natl Cancer Inst 40:307-318, 1968.

7. Estrela-Lima A, Araujo MS, Costa-Neto JM et al: Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates, BioMed Central Cancer 10:256-269, 2010.